Suchergebnisse - "ROS1 positive"

PubPharm (34)

1

A phase IB study of crizotinib in pediatric malignancies : A phase 1B study of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies

enthalten in: WHO International Clinical Trials Registry Platform | 2023

2

A phase IB study of crizotinib in pediatric malignancies : A phase 1B study of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies

enthalten in: WHO International Clinical Trials Registry Platform | 2023

3

ROS1-positive non-small cell lung cancer (NSCLC) : biology, diagnostics, therapeutics and resistance

enthalten in: Journal of drug targeting | 2022

von Yu, Z. | Wang, M. | Zhou, W. | +6

4

Study with investigational drug PF-06463922 in patients with a specific type of advanced lung cancer : Phase 1/2 study of PF-06463922 (an ALK/ROS1 tyrosine kinase inhibitor) in patients with advanced non-small cell lung cancer harboring specific molecular alterations.

enthalten in: WHO International Clinical Trials Registry Platform | 2022

5

Study with investigational drug PF-06463922 in patients with a specific type of advanced lung cancer : Phase 1/2 study of PF-06463922 (an ALK/ROS1 tyrosine kinase inhibitor) in patients with advanced non-small cell lung cancer harboring specific molecular alterations.

enthalten in: WHO International Clinical Trials Registry Platform | 2022

6

Original Protocol for Lorlatinib Continuation Study : LORLATINIB (PF-06463922) CONTINUATION PROTOCOL: AN OPEN-LABEL, SINGLE-ARM CONTINUATION STUDY FOR PARTICIPANTS WITH ALK-POSITIVE OR ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) CONTINUING FROM PFIZER SPONSORED LORLATINIB CLINICAL STUDIES

enthalten in: WHO International Clinical Trials Registry Platform | 2022

7

Original Protocol for Lorlatinib Continuation Study : LORLATINIB (PF-06463922) CONTINUATION PROTOCOL: AN OPEN-LABEL, SINGLE-ARM CONTINUATION STUDY FOR PARTICIPANTS WITH ALK-POSITIVE OR ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) CONTINUING FROM PFIZER SPONSORED LORLATINIB CLINICAL STUDIES

enthalten in: WHO International Clinical Trials Registry Platform | 2022

8

TRUST-II : A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of AB-106 in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors

enthalten in: WHO International Clinical Trials Registry Platform | 2022

9

TRUST-II : A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of AB-106 in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors

enthalten in: WHO International Clinical Trials Registry Platform | 2022

10

ROS1-positive non-small cell lung cancer (NSCLC): biology, diagnostics, therapeutics and resistance

enthalten in: Journal of drug targeting | 2022

von Yu, Z. | Wang, M. | Zhou, W. | +6